Redeye is encouraged that Q-linea now has received their first order on instruments and consumables. The completion of this first-order is positive and is done before the clinical study's completion. These are straightforward preparations from the partner Thermo Fisher to be ready for commercialization as soon as the clinical study is finalized and the CE-IVD approval. We do not change our estimates or outlook at this time. We reiterate our motivated value of SEK 180 per share in our base scenario.